Skip to main content
Defiance International

The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.

In vitro record. The journal of headache and pain, 2023.

  • Cell
  • 2023

Authorship

Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.

Source: the abstract of PMID 37231350. Checked Verification: Evidence verified by machine against declared source

This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.

Verify a lot

Evidence verified by machine against declared source

Open declared source

Key facts

Design
Not reported
System
Cell
Scale
Not reported
Comparator
Present
Journal
The journal of headache and pain
Year
2023
PMID
37231350
Verification
Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Full-text availability
Abstract only

Technical summary

Research question

Our objective was to determine whether Lu AG09222, an investigational humanized monoclonal antibody directed against PACAP ligand, would inhibit the PACAP-signaling cascade by abolishing its vasodilatory and headache-inducing abilities.

Study design

In a randomized, double-blind, parallel-group, single-dose, placebo-controlled study of Lu AG09222, healthy volunteers aged 18–45 years without history of headache disorders were randomly allocated to three treatment sequences (1:2:2) on two experimental infusion visits with 9 ± 3 days’ interval: placebo + saline + saline (n = 5), placebo + PACAP38 + VIP (n = 10), and Lu AG09222 + PACAP38 + VIP (n = 10).

Participants or experimental system

All randomized participants who received either placebo or Lu AG09222 were included in the safety analysis; all participants who received an infusion of PACAP38 or saline and had a valid pre-infusion STA diameter measurement and a valid AUCSTA-PACAP38 measurement on visit 1 were included in analyses related to the PACAP38 infusion; and all participants who received a VIP or saline infusion and had a valid pre-infusion STA diameter measurement and a valid AUCSTA-VIP measurement on visit 2 were included in analyses related to the VIP infusion.

Comparator

This was a phase 1, interventional, randomized, double-blind, parallel-group, placebo-controlled, single-dose study investigating the effect of Lu AG09222 in a headache model with healthy volunteers.

Outcomes examined

Vascular parameters (superficial temporal artery [STA] diameter and radial artery [RA] diameter measured by high-resolution ultrasonography; facial flushing measured by speckle contrast imager), heart rate and headache were documented before Lu AG09222 or placebo infusion and PACAP38 or saline infusion at visit 1 and before VIP or saline infusion at visit 2.

Key findings

In participants who received Lu AG09222 + PACAP38 infusion, there was a significantly lower STA diameter (mean (SE) [95% CI] AUC ‒35.4 (4.32) [‒44.6, ‒26.3] mm × min; P < 0.0001) compared to participants who received placebo + PACAP38 infusion.

Not reported in the declared source: Methods, Study scale. Not published in this record: Intervention or exposure.

Limitations and uncertainty

This study has a relatively small sample size.

Cite

Cite the study

The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.
Rasmussen NB, Deligianni C, Christensen CE et al. The journal of headache and pain. 2023. PMID 37231350

The study and its abstract belong to their authors and publisher. Cite them for anything the study found.

Report an error

If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.

The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.

The report form runs in the interactive page. Open this record with scripts enabled to send a report.

Corrections on this record

No correction has been recorded for this record.

Method sheet

No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.